Literature DB >> 35550799

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update.

Andrei S Purysko1, Paul Nikolaidis2, Gaurav Khatri3, Moises Auron4, Alberto Diaz De Leon5, Dhakshinamoorthy Ganeshan6, John L Gore7, Rajan T Gupta8, Simon Shek-Man Lo9, Andrej Lyshchik10, Stephen J Savage11, Andrew D Smith12, Myles T Taffel13, Don C Yoo14, Mark E Lockhart15.   

Abstract

Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic imaging is the most valuable component of surveillance, as most relapses and cases of disease progression are identified when patients are asymptomatic. Understanding the strengths and limitations of the various imaging modalities for the detection of disease, recurrence, or progression is essential when planning follow-up regimens. This document addresses the appropriate imaging examinations for asymptomatic patients who have been treated for RCC with radical or partial nephrectomy or ablative therapies. It also discusses the appropriate imaging examinations for asymptomatic patients with localized biopsy-proven or suspected RCC undergoing active surveillance. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2022 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Appropriate Use Criteria; Appropriateness Criteria; CT; Diagnostic imaging; MRI; Renal cell carcinoma; Surveillance; Ultrasound; X-ray

Mesh:

Year:  2022        PMID: 35550799     DOI: 10.1016/j.jacr.2022.02.015

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  1 in total

Review 1.  Renal Cell Carcinoma Associated With HIV/AIDS: A Review of the Epidemiology, Risk Factors, Diagnosis, and Treatment.

Authors:  Zhiqiang Zhu; Yihang Zhang; Hu Wang; Taiyi Jiang; Mengmeng Zhang; Yu Zhang; Bin Su; Ye Tian
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.